AIM
NYMX

Acrospire Investment Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Acrospire Investment Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,773
Closed -$8K – 1594
2017
Q2 		$8K Sell
1,773
-3,600
-67% -$14.8K 0.01% 1869
2017
Q1 		$20K Sell
5,373
-19,520
-78% -$64.2K 0.02% 1638
2016
Q4 		$66K Buy
+24,893
New +$77.2K 0.03% 1220

Other funds holding NYMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

Acrospire Investment Management's NYMX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2017, closing a stake of 1,773 shares — an estimated $8K sold.

Acrospire Investment Management first reported a position in NYMX in Q4 2016 and held it in 3 quarters. The position peaked at $66K in Q4 2016. 45 funds tracked by Wall St. Rank hold NYMX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,773 Nymox Pharmaceutical Corp shares in Q3 2017, an estimated $8K.
  • Acrospire Investment Management first reported a position in Nymox Pharmaceutical Corp in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Nymox Pharmaceutical Corp position peaked at $66K in Q4 2016.
  • 45 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.